The global landscape of metabolic medicine has been fundamentally altered by the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists. While…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
